Innovating Thyroid Health with Genomics and Predictive Algorithms through Collaborative Excellence (InnoThyroGen)

Global research indicates that millions of people suffer from thyroid disorders, such as hypothyroidism, hyperthyroidism, autoimmune diseases, and tumors, with nearly 60% of them unaware of their condition. Autoimmune thyroid diseases, notably Hashimoto's thyroiditis and Graves' disease, are the most prevalent, affecting about 5% of the population. Thyroid cancers are also on the rise, with significant increases in detection over recent decades. Despite various treatment and diagnostic options, many face misdiagnosis, ineffective treatments, and diminished quality of life. Levothyroxine, a synthetic thyroid hormone, is widely prescribed in Europe and the USA, yet 20-50% of patients experience improper dosing, necessitating frequent adjustments. Antithyroid medications can cause severe side effects, underscoring the need for careful management of thyroid diseases to avoid increased healthcare costs and lost productivity. Current treatment approaches, often not personalized, overlook genetic predispositions and environmental factors. Advances in genomics, such as next-generation sequencing (NGS) and the polygenic risk score (PRS), offer new opportunities for personalized medicine. These tools, combined with electronic health records (EHR) and lifestyle data, can improve disease prediction and prevention strategies. Pharmacogenomics further enables tailored drug treatment based on individual genetic profiles, promising more effective and personalized care. The design of thyroid disease gene panels and the development of innovative and digital solutions based on artificial intelligence stand as pivotal advancements. These could markedly accelerate the integration of more personalized and cost-effective approaches into clinical practice, heralding a new era of precision medicine for thyroid disorders.